Analyst consensus rating
Evommune Analyst Rating: Buy
Direct answer
Evommune's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $22.33.
Forecast evidence checked October 17, 2026.
Get free Evommune email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.17
- Average price target
- $22.33
- High price target
- $30.00
- Low price target
- $8.00
- Low target gap
- +54.7%
- Target upside
- +332%
- High target gap
- +480.3%
- Target range width
- 425.5%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Evommune?
Evommune has a verified Buy consensus. The same dataset has an average price target of $22.33.
How far are Evommune's low and high targets from the recorded price?
The low target implies +54.7%, while the high target implies +480.3%.
How many analysts are included in Evommune's consensus?
The verified consensus includes 9 analysts.
How is Evommune's target upside or downside calculated?
The average target of $22.33 is divided by the recorded price of $5.17, then one is subtracted to produce +332%. This does not guarantee a future return.
When was Evommune's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.